{
    "nct_id": "NCT03224767",
    "official_title": "Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas",
    "inclusion_criteria": "* Pre-registration: Patients must have local diagnosis of papillary craniopharyngioma and have tissue slides available for submission to central pathology review; central pathology review will include immunohistochemistry (IHC) testing for BRAF V600E mutation (VE1 clone) and beta-catenin IHC (membranous, non-nuclear pattern) if needed to confirm diagnosis of papillary craniopharyngioma\n* Histologically proven papillary craniopharyngioma as documented by central pathology review with positive BRAF V600E mutation by IHC\n* Measurable disease and/or non-measurable disease\n\n  * Measurable disease, defined as bidimensionally measurable lesions with clearly defined margins by magnetic resonance imaging (MRI) scans, with a minimum diameter of 10 mm in both dimensions\n  * Progressive disease required in cohort B, defined as an increase in the bidirectional area by 25% within the past 13 months after surgery or radiation; progressive or recurrent disease is not required in cohort A, but is allowed provided it is a new diagnosis and patient has not received prior treatment.\n* Prior treatment\n\n  * Cohort A: No prior therapy received other than surgery\n  * Cohort B: Prior radiation therapy required (any type of prior radiation is allowed)\n\n    * For patients treated with external beam radiation therapy, interstitial brachytherapy or radiosurgery, an interval of >= 3 months must have elapsed from completion of radiation therapy to registration\n    * Recovered to Common Terminology Criteria for Adverse Events (CTCAE) grade 1 or less toxicity attributed to radiation with exception of alopecia, fatigue\n  * For patients enrolling on Cohort A or Cohort B:\n\n    * For patients treated with surgery, an interval of >= 21 days must have elapsed prior to registration\n    * No prior treatment with BRAF or MEK inhibitors\n    * Steroid dosing stable for at least 4 days prior to registration\n* Not pregnant and not nursing; for women of childbearing potential only, a negative pregnancy test done =< 7 days prior to registration is required\n* ECOG performance status =< 2\n* Comorbid conditions\n\n  * No evidence of active bleeding, bleeding diathesis, or hemoptysis (>= 1/2 teaspoon of red blood) =< 8 weeks prior to registration\n  * No evidence of intracranial hemorrhage =< 4 weeks prior to registration\n  * Patients who have experienced thromboembolic event within 6 months prior to registration must be on stable therapeutic anticoagulation for at least 4 weeks prior to registration\n  * No symptomatic congestive heart failure (New York Heart Association class II, III, or IV) within 6 months prior to registration\n  * No current unstable angina or uncontrolled arrhythmia\n  * No uncontrolled hypertension at time of registration (blood pressure [BP] > 150/95 despite antihypertensive therapy)\n  * No known history of prolonged QT syndrome\n  * No known history of ventricular arrhythmia within 6 months of registration\n  * No known history of uveitis or iritis =< 4 weeks prior to registration\n  * No known history of or evidence of retinal pathology that is considered a risk factor for neurosensory retinal detachment, retinal vein occlusion (RVO), or neovascular macular degeneration within 12 months of registration\n  * No known history of chronic lung disease\n* Concomitant medications\n\n  * Chronic concomitant treatment with strong CYP3A4 inducers or CYP3A4 inhibitors is not allowed; patients must discontinue the drug at least 14 days prior to study registration\n  * Chronic concomitant treatment with CYP1A2 substrate is not allowed; patients must discontinue the drug at least 14 days prior to study registration\n* Absolute neutrophil count >= 1500/mm^3\n* Platelets >= 100,000/mm^3\n* Creatinine =< 1.5 mg/dL OR creatinine clearance >= 45mL/min\n* Bilirubin =< 1.5 upper limit of normal (ULN)\n* Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 ULN\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}